A shadow economy for unapproved weight-loss medications is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.
Experimental Drug Acquiring Traction Online
The experimental drug, which remains in clinical trials, is being promoted by social media influencers for its alleged weight-reducing properties. Followers are urged to contact these accounts privately for supplier links, while also obtaining promotional offers.
Active Commerce on Messaging Platforms
Additionally, a flourishing market exists on Telegram, where communities with thousands of members share “before and after” photos, administration instructions and claims of next-day UK delivery. Vendors market the substance there before redirecting customers to WhatsApp for purchases.
Understanding The Experimental Drug
This medication is an investigational injection developed by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could assist patients lose up to a quarter of their total weight. Referred to as the “triple G”, the substance is being promoted digitally as the next Ozempic.
Healthcare Professionals Voice Concerns
Nevertheless, physicians and pharmacists have warned that the sale of what is still an unlicensed medication in the United Kingdom is a cause for concern and could lead to users administering substances of uncertain source.
Several experts said the popularity for retatrutide could be connected to the rising price of licensed slimming treatments such as Mounjaro.
Regulatory Status and Implementation
Marketing the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be promoted or supplied for human use under the British medical regulations.
Some influencers try to circumvent the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and distribution can still breach pharmaceutical, advertising, and consumer regulations, potentially leading to fines, prosecution or prison.
Service Reaction and Content Elimination
Based on the social media company, the service has taken down problematic content and banned associated keywords and search suggestions. The organization stated it was dedicated to keeping the platform secure and allocating resources in enhancing compliance measures.
Online Marketplace Operations
Research also discovered communities with up to 9,000 participants selling the experimental drug using Telegram's integrated discovery tool, which operates like a public directory. Typing “retatrutide” instantly displays channels with thousands of members, populated with photos of weight loss, glowing testimonials and step-by-step guides for preparing or administering at home.
Within minutes of joining one community, a vendor shared contact information, where most transactions take place. The seller provided an instruction manual and promised shipping within two days. When questioned whether the product was genuine, one seller said: “You can’t be sure.” Another provided a photo of a alleged testing documentation. None inquired about weight, health issues or past usage.
Item Details and Costs
Inside these groups, messages display black plastic packages with Royal Mail labels, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, mixed at residence with purified liquid, or pre-filled pens usually sold at £160 for 20mg. When questioned how much time a pen should be used, sellers give conflicting responses varying between a few weeks to “depends on your body”.
Service Moderation and Safety Actions
A spokesperson for Telegram said it regularly monitored dangerous material on its service including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“Individuals are injecting materials they can’t verify. Although the science behind this drug is valid, these online versions may not include what they advertise,” said Jason Murphy, the director of pharmacy at a pharmacy service.
A medical professional of Asda Online Doctor linked the surge in demand to recent price rises for authorized weight-loss medications such as Mounjaro. “With prices increasing, patients are turning to social media. But counterfeit treatments are extremely risky. You can’t be certain what’s inside or whether the environment they were made in was clean,” she explained.
Her team has previously encountered individuals injured by personal administration from unverified sources. “We understand the disappointment, but purchasing from messaging apps or communication platforms is taking chances with your health,” said Wyllie. “These materials could be impure or improperly measured.”
Manufacturer Statement
A spokesperson from the pharmaceutical company stated the substance was in third stage research studies and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they said, adding that any product “falsely representing itself as a company experimental substance not yet authorized … may expose users to potentially significant medical dangers”.
